Book · Julian R. Sterling
A Practitioner's Guide to Risk-Adjusted NPV for Drug Assets: Probability of Success by Phase, Peak Sales Forecasting, Launch Curves, Exclusivity and Loss of Exclusivity, IRA Price Negotiation, Licensing Deal Terms and Pipeline Sum-of-the-Parts
A drug asset does not behave like an ordinary business. Most programs fail before approval, the ones that succeed earn for a limited period of exclusivity, and the cash goes out years before it comes back. Risk-adjusted NPV (rNPV) handles all three: each cash flow is weighted by the probability that the program survives to earn or spend it, and discounted at a rate that reflects market risk only. It is the common language of business development teams, biotech analysts, venture and crossover investors and biotech CFOs, and the method behind most licensing negotiations.
The Biotech Valuation Handbook follows one fictional clinical-stage company, Veltrana Therapeutics, Inc., with three product candidates. VLT-201, an oral small molecule in Phase 2b for ulcerative colitis, carries a 19.53 percent likelihood of approval, peak US net sales of $648.00 million and an rNPV of $71.09 million against an unrisked NPV of $718.85 million; a positive Phase 2b readout would lift its value to $360.92 million. VLT-305, a Phase 1 bispecific antibody, is worth -$25.16 million developed alone but $61.01 million out-licensed under a term sheet with a headline value of $325.00 million. The sum-of-the-parts gives 5.61 dollars per share against net cash of 7.07 dollars, and 7.09 dollars with the licence. Along the way the book uses the published BIO, Informa and QLS success-rate benchmarks, builds the patient funnel and gross-to-net, models exclusivity, Paragraph IV and biosimilar erosion, applies the IRA negotiation timing, and runs eight sensitivities. Every number ties to live, unlocked Excel workbooks.
The live Excel workbooks behind every table in the book. Blue inputs, black formulas, zero circular references, a Controls tab that must read zero. No sign-up required for book readers.
Appendix A, chapters 1 to 14
Eleven tabs, 2027 to 2050 in USD millions: README, Inputs, VLT201_Revenue, VLT201_rNPV, VLT305, Deal_Marlowe, VLT410_Tree, SOTP, Sensitivities, Runway and Controls.
Download Biotech_rNPV_Workbook.xlsx122 KBStandalone practitioner model
A single-asset rNPV model prefilled with VLT-201 ($71.09 million): probabilities by phase, patient funnel, launch curve, IRA price, loss of exclusivity and licence income, with a check cell.
Download rNPV_Drug_Asset_Model.xlsx14 KBWant the standalone model first? Open the free rNPV drug asset valuation model page for the worked example and Excel download.
Related titles. Full list on the author page.